Johnson & Johnson reports consistent TREMFYA fistula remission across Crohn's subgroups

Johnson & Johnson said on October 12, 2026, that new Phase 3 data from the FUZION study showed consistent combined fistula remission with TREMFYA (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula. The prespecified subgroup analyses are being presented at the American College of Gastroenterology 2026 Annual Scientific Meeting and build on previously reported Week 24 results from the overall study population.

In the subgroup analyses, patients with greater luminal disease activity at baseline (CDAI of 220 or more) reached combined fistula remission of 30% with the 100 mg subcutaneous every eight weeks dose and 21% with the 200 mg subcutaneous every four weeks dose, versus 0% with placebo. Patients with prior biologic exposure reached 21% and 29%, respectively, versus 5% with placebo.

Remission rates were also reported for patients with and without proctitis at baseline. Patients with proctitis reached 26% and 27%, respectively, versus 12% with placebo, and patients without proctitis reached 29% and 27%, respectively, versus 10% with placebo. Johnson & Johnson said adverse events were consistent with the known safety profile of TREMFYA in Crohn's disease.